Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of 5th Product License for MultiXThick Barium X-ray Contrast


May 17, 2021 (Source) – Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Traveler”) is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick Barium Sulfate Suspension containing 105% w / v barium sulfate suspension for oral and rectal administration from the gastrointestinal tract.

Voyageur has built a complete line of barium x-ray contrast media for worldwide sales and distribution. The following products have been licensed:

  • SmoothX – For the CT market
  • HDX – For the fluoroscopy market
  • LDX – For the fluoroscopy market
  • MultiXthin – For the fluoroscopy market
  • MultiXthick – For the fluoroscopy market

Voyageur is focused on deploying all of its products in a timely manner. Smoothies for CT scans are one of the best-selling products in the United States and Canada. Voyageur is focused on launching SmoothX as an initial product to the market. Voyageur is currently optimizing blend formulations and manufacturing procedures to bring its newly formulated products into compliance with GMP and HC guidelines. Voyageur will work with a Canada-based imaging clinic to perform clinical trials on patients to ensure our product meets and exceeds computed tomography requirements before entering the market. Voyageur plans to ensure that the highest quality products are created prior to the first phase of marketing, sales and distribution in the Canadian, US and international markets.

FDA applications are ongoing and our goal is to acquire licenses for FDA devices to coincide with the deployment of our products.

Voyageur has initiated business and product development work with Dash Consulting to develop additional new and improved products for the computed tomography, MRI and fluoroscopy markets. Voyageur plans to create several new value-added products to our product portfolio. Our goal is to create new products and product lines that exceed the performance of products currently available on the market. These products are developed to complement and enhance the latest technological advances in radiographic technology. Voyageur believes that these new products and their development will bring significant added value and allow our company to capture targeted market segments.

About Voyageur

Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the symbol VM. Voyageur focuses on the development of barite and iodine, mineral active pharmaceutical ingredients (APIs). The short-term goal is to develop barium and iodine radiocontrast pharmaceuticals. Voyageur’s goal is to initially generate positive short-term cash flow from its operations using GMP third-party pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur plans to build all the necessary infrastructure to become 100% self-sufficient with all of the manufacturing. Voyageur has a 100% interest in three barium sulfate (barite) projects, including two grade properties suitable for the industrial barite market, with interests in an iodine, lithium and bromine brine project potentially high quality located in Utah, United States.

Voyageur is moving forward with its business plan to become the only fully integrated company in the medical field of radiographic contrast, controlling all primary input costs under the motto: “From Earth to Bottle”

For more media information or to arrange an interview, please contact:

Brent Willis
President and CEO

Ron love
T 403.818.6086

Forward-looking information

This press release may contain certain forward-looking information and statements, including, without limitation, statements relating to the commercial launch of its products, including the timing of the marketing, sale and distribution of MultiXthin and other products of the Company’s barium radiographic contrast, the ability to obtain licenses in international jurisdictions and, to do so quickly, based on existing HC approvals, the Company’s ability to obtain the necessary HC approvals for HC products. additional barium X-ray contrast, the closing and timing of the second tranche of the Offer, and obtaining the necessary approvals from the TSX Venture Exchange. All statements included herein, except statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of the assumptions used to develop such forward-looking information and a description of the risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at ‘address Voyageur does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Notice to readers

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Source link

About Catherine Sherrill

Check Also

Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28%

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us …

Leave a Reply

Your email address will not be published. Required fields are marked *